linjc16/ctgov huggingface dataset:
CXCL2/CXCL8 Promote Intervertebral Disc Degeneration

Study Overview
=================
Brief Summary
-----------------
Low back pain (LBP) is the largest cause of morbidity in the world, and about 80% of Chinese people are affected in their lifetime. Although the prevalence of IDD gradually increases with age, IDD is very common among subjects under 30 years old. In addition to age, there are other factors, such as excessive or uneven mechanical load, obesity, genetics, nutrition, trauma and gender. In addition, it is not clear whether the heavy physical load associated with occupation is an important risk factor for IDD. Some studies have found that IDD is more common among athletes than the general population. Due to the complexity and multifactorial nature of IDD, its pathogenesis and risk factors are still unclear, which seriously hinders the rational stratification of LBP patients and limits the development of personalized treatment.

Official Title
-----------------
Study on the Correlation Between CXCL2/CXCL8 and the Degree of Intervertebral Disc Degeneration and Radiological Progress

Conditions
-----------------
Cytokine, Intervertebral Disc, Degenerative

Intervention / Treatment
-----------------
* Diagnostic Test: CXCL2/CXCL8


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: It meets the diagnostic criteria of lumbar disc degeneration; No previous history of spinal surgery; Good ability of independent behavior and cooperation in completing research; The patient is aware of this study and has signed the consent form. Exclusion Criteria: Patients with spinal tumor, infection, tuberculosis and other diseases; Patients with claustrophobia; Parkinson's syndrome patients; Poor cooperation, Poor image quality; Patients with osteoporosis.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| pirffmann 2 grade<br> | Diagnostic Test: CXCL2/CXCL8<br>* Detecte CXCL2/8 content in nucleus pulposus and peripheral blood of patients in each group<br>|
| pirffmann 3 grade<br> | Diagnostic Test: CXCL2/CXCL8<br>* Detecte CXCL2/8 content in nucleus pulposus and peripheral blood of patients in each group<br>|
| pirffmann 4 grade<br> | Diagnostic Test: CXCL2/CXCL8<br>* Detecte CXCL2/8 content in nucleus pulposus and peripheral blood of patients in each group<br>|
| pirffmann 5 grade<br> | Diagnostic Test: CXCL2/CXCL8<br>* Detecte CXCL2/8 content in nucleus pulposus and peripheral blood of patients in each group<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CXCL2/8 content | CXCL2/CXCL8 content of nucleus pulposus | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cytokine, chemokine, Intervertebral Disc Degeneration
Drinking Water PFAS, Pregnancy Outcome and Maternal Morbidity

Study Overview
=================
Brief Summary
-----------------
The aim of the project is to assess the association between exposure to per- and polyfluoroalkyl substances (PFAS) via drinking water in pregnancy and birth outcomes (i.e. growth retardation, premature birth, and congenital developmental defects) and maternal morbidity (gestational hypertension, diabetes and preeclampsia) in a prospective population-wide register study.

Official Title
-----------------
Drinking Water PFAS, Pregnancy Outcome and Maternal Morbidity

Conditions
-----------------
Birth Weight, Small for Gestational Age at Delivery, Large for Gestational Age at Delivery (Macrosomia), Diabetes, Gestational, Hypertension in Pregnancy, Preeclampsia, Congenital Malformation

Intervention / Treatment
-----------------
* Other: Per- and polyfluoroalkyl substances (PFAS)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant women residing in Swedish localities with a population exceeding 10,000 inhabitants and giving birth during 2012-2018 Exclusion Criteria: Lack of data of PFAS levels in municipal drinking water (entire localities excluded) Mothers not living in the study area consistently between first trimester and four years prior to birth
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Per- and polyfluoroalkyl substances (PFAS)|Assess the association between exposure to per- and polyfluoroalkyl substances (PFAS) via drinking water in pregnancy and birth outcomes (i.e. growth retardation, premature birth, and congenital developmental defects) and maternal morbidity (gestational hypertension, diabetes and preeclampsia) in a prospective population-wide register based cohort.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Birth outcome - birthweight | grams as measured at birth | at birth | 
| Birth outcome - Small for gestational age (SGA) | <-2 standard deviations (SD) from the average weight at the gestational age and sex at partus (Marsal et al. 1996. Acta Paediatr 85(7): 843-848) | at birth | 
| Birth outcome - Large for gestational age (LGA) | >2 standard deviations (SD) from the average weight at the gestational age and sex at partus (Marsal et al. 1996. Acta Paediatr 85(7): 843-848) | at birth | 
| Birth outcome - major congenital malformations | ICD10- codes: Q00-Q99 within the first 28 days postpartum, categorized as major congenital malformations according to European Surveillance of Congenital Anomalies (EUROCAT 2014) | at birth | 
| Maternal health - Gestational hypertension/preeclampsia | ICD10-codes: O13-O14. Diagnosis at maternal or primary care | during gestation | 
| Maternal health - Gestational diabetes mellus | ICD10-codes: O24 (excluding pregestational diabetes). Diagnosis at maternal or primary care | during gestation |
Fluid Challenge Impact in the Portal Vein Pulsatility Depending on the Fluid Responsivness Status

Study Overview
=================
Brief Summary
-----------------
Portal vein pulsatility index is a marker of venous congestion evaluated by point of care ultrasound. It is associated with acute kidney injury, especially in critically ill patients. It may be considered as a dynamic marker. The investigators hypothesized that portal vein pulsatility index is higher after a fluid challenge only in patient without preload dependence in critically ill patients with cardiovascular insufficiency.

Official Title
-----------------
Fluid Challenge Impact in the Portal Vein Pulsatility Depending on the Fluid Responsivness Status

Conditions
-----------------
Cardiovascular Insufficiency, Venous Congestion

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: vasopressor requirement to maintain mean arterial pressure >65mmHg AND at least one of the following criteria: arterial lactate >2mmol/L; capillary refill time >3s; mottling score >1; diuresis <0,5mL/h for more than 6hours. Exclusion Criteria: Diameter of vena cava <20mm Cirrhosis Pregnancy Severe acute pulmonary edema Phototype 4 or 5 Patient opposition to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort<br>Population: Critically ill patient with: cardio circulatory insufficiency as defined by vasopressor requirement and at least one of the following criteria: arterial lactate >2mmol/L ; capillary refill time >3s ; mottling score >1 ; diuresis <0,5mL/h for more than 6hours diameter of inferior vena cava >20mm Protocol: Administration of a fluid challenge (4mL/kg of Ringer Lactate) over 5 to 10 min. Point of care ultrasound evaluation of portal vein pulsatility index and Vexus criteria before and after the fluid challenge ; fluid challenge induced cardiac index variations estimated by pulse contour analysis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Portal vein pulsatility index variation induced by the fluid challenge (%), defined by: Portal vein pulsatility index before the fluid challenge - portal vein pulsatility index after the fluid challenge. | Portal vein pulsatility index is defined as the (maximal velocity - minimal velocity) / maximal velocity assessed with doppler in portal vein estimated with point of care ultrasound. | One hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Point of care ultrasound, Portal vein pulsatility index, Venous congestion, Preload dependence
Evaluation of Clinical Utility of Non-invasive Hemodynamic Monitoring Device

Study Overview
=================
Brief Summary
-----------------
In patients undergoing surgery under general anesthesia, the clinical utility of non-invasive hemodynamic status monitoring equipment using HemoVista is compared with invasive hemodynamic status monitoring equipment FloTrac.

Detailed Description
-----------------
For patients who are scheduled to monitor invasive blood pressure, invasive hemodynamic monitoring using FloTrac and additional HemoVista sensors are attached and output data are obtained at the same time during general anesthesia. FloTrac is used to conduct conventional anesthesia and fluid therapy, and the accuracy of HemoVista, a non-invasive hemodynamic monitoring equipment, is compared through prospective observational studies.

Official Title
-----------------
Evaluation of Clinical Utility of Non-invasive Hemodynamic Monitoring Device (HemoVista™) in the Clinical Filed

Conditions
-----------------
Cardiovascular Complication

Intervention / Treatment
-----------------
* Other: HemoVista


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients aged 20 or older who undergo surgery under general anesthesia for more than two hours invasive close hemodynamic monitoring with FloTrac is needed Exclusion Criteria: problems in site where HemoVista is attached

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: HemoVista|additional attatchment of non-invasive hemodynamic monitoring HemoVista with FloTrac|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| degree of agreement in cardiac output | degree of agreement in cardiac output between HemoVista and FloTrac | during surgery |
Assessment of Patient Experience and Needs for Patients Undergoing Invasive Inguinal Lymph Node Procedures for Penile Cancer

Study Overview
=================
Brief Summary
-----------------
To learn more about the patient experience undergoing inguinal (in the groin) lymph node procedures for penile cancer during and after surgery.

Detailed Description
-----------------
Objectives Primary Objective: To understand the lived experience of patients undergoing invasive inguinal lymph node procedures. Secondary Objective: To determine factors that influence decisions and improve experience for patients who need invasive inguinal lymph node procedures.

Official Title
-----------------
Assessment of Patient Experience and Needs for Patients Undergoing Invasive Inguinal Lymph Node Procedures for Penile Cancer

Conditions
-----------------
Penile Cancer

Intervention / Treatment
-----------------
* Behavioral: Quality of Life Questionnaires
* Behavioral: Patient Educational Needs
* Behavioral: Symptom Management


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: --Patients diagnosed with penile cancer who have undergone invasive inguinal node procedures (ILND and/or DSNB) and are at least 6 months post-procedure Exclusion Criteria: Patient's ≤18 years of age Patients who have not undergone invasive surgical procedures involving the inguinal lymph nodes Non-English-speaking patients For interviews: people who are physically and/or cognitively incapable of participating in a 60minute telephone interview as determined by a clinical provider or the patient.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Semi-structured interviews<br>Participants with penile cancer who have undergone invasive inguinal lymph node procedure will be recruited to participate in study via telephone recruitment. | Behavioral: Quality of Life Questionnaires<br>* Identify what interventions may be helpful in improving quality of life.<br>Behavioral: Patient Educational Needs<br>* Identify what interventions may be helpful in improving patient educational needs<br>Behavioral: Symptom Management<br>* Identify what interventions may be helpful in improving symptom management Improve symptom management<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decision Regret Scale (DRS) questionnaires | Score Scale ranges (1-5) Strongly Agree Agree Agree nor Disagree Disagree Strongly Disagree | through study completion; an average of 1 year |
Artificial Intelligence Evaluation of Fillings

Study Overview
=================
Brief Summary
-----------------
The goal of this Non-Interventional Clinical Research is to detect the prevalence and distribution of filling and overhanging filling without the need for additional bitewing radiographs using panoramic images, based on a deep CNN (Convolutional Neural Network) architecture trained through supervised learning. In this study, retrospectively obtained radiographs were used in the development of artificial intelligence models for relevant situations. These datasets were obtained from the images of the patients who applied to ESOGU (Eskişehir Osmangazi University) Dentistry Faculty, Dentomaxillofacial Radiology clinic for various dental purposes. Eskisehir Osmangazi University Non-Interventional Clinical Research Ethics Board (decision date and decision number: 04.10.2022/22) approved the study protocol. The principles of the Helsinki Declaration were followed in the study.

Official Title
-----------------
A Yolo-V5 Approaches to Evaluation of Filling and Overhanging Filling: An Artificial Intelligence Study

Conditions
-----------------
Dentomaxillofacial Radiology

Intervention / Treatment
-----------------
* Diagnostic Test: Panoramic Radiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Images of individuals in the permanent dentition period Artifact-free images in the examination region Individuals with a history of restorative dental treatment Exclusion Criteria: Images of individuals in mixed dentition Radiographic images obtained by incorrect positioning of the patient or containing artifacts
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Filling<br> | Diagnostic Test: Panoramic Radiography<br>* this retrospective study includes analysis of radiographs previously taken from patients for various purposes<br>|
| Overhanging Filling<br> | Diagnostic Test: Panoramic Radiography<br>* this retrospective study includes analysis of radiographs previously taken from patients for various purposes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The success of artificial intelligence models for filling and overhanging filling | It is obtained by calculating the sensitivity, precision, and F1 scores values for filling and overhanging filling. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dental filling, dentistry, deep learning,
Diaphragmmatic Muscle Strength and Balance in Women With Dysmenorhea

Study Overview
=================
Brief Summary
-----------------
Analysis of stabilometric and respiratory variables in patients with dysmenorrhea during the first day of the menstrual cycle and any other day outside the cycle.

Detailed Description
-----------------
Sociodemographic variables such as age, height, body mass index. Respiratory variables such as maximum inspiratory pressure (MIP), MIP reference %, and MIP predictive value. Stabilometric variables we will measure the balance in condition of eyes open and eyes closed bipodal support and eyes open in monopodal support

Official Title
-----------------
Diaphragmmatic Muscle Strength and Balance in Women With Dysmenorhea

Conditions
-----------------
Dysmenorrhea Primary

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult women with primary dysmenorrhea. Not having had any type of childbirth (natural, caesarean section, etc). Not be positive in COVID. Antigen test in the last 24 hours or negative PCR in the last 48 hours. Exclusion Criteria: Receive medical treatment during research. Have any orthopedic, neurological or systemic disease diagnosed other than primary dysmenorrhea. Be in follow-up with any medical treatment that does not be primary dysmenorrhea Women with a history of trauma or surgical treatment who involve the musculoskeletal system in the last year. Use of analgesics in the last 48 hours. Consumption of alcohol in the last 24 hours. Have a history or suspicion of pregnancy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| dysmenorrhea<br>primary dysmenorrhea | |
| control<br>control not pain | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Balance | stabilometric variables in bipodal and monopodal support | 2 months | 
| diaphragmatic muscle strength | diaphragmatic muscle force through the maximum inspiratory pressure in the mouth | 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sociodemographic variables | sociodemographic variables such as age, body mass index, personal data record, and data record related to pain and dysmenorrhea | 2 monsths | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dysmenorrhea, diaphragm, balance, muscular strength
Progesterone-Primed Ovarian Simulation in Controlled-ovarian Simulation of Infertile PCOS Patients

Study Overview
=================
Brief Summary
-----------------
The study evaluated the safety and efficacy of the progesterone-primed ovarian stimulation (PPOS) coupled with gonadotropin (FSH) for infertile women with polycystic ovary syndrome (PCOS) who were assigned for ICSI and frozen blastocyst transfer. 200 infertile women were divided randomly into Group C, which received Cetrorelix injection (0.25 mg daily) on day-6, and Group S, which received oral dydrogesterone (20 mg/day) on day-2 of the menstrual cycle till the trigger day. All patients received an FSH injection of 225 IU daily from day-2 till triggering day. ICSI was performed and day-5 blastocysts underwent vitrification ultra-rapid cryopreservation till being transferred. Outcomes included the ability of PPOS to suppress the premature luteinizing hormone (LH) surge and prevent the development of ovarian hyperstimulation syndrome (OHSS), the incidence of profound LH suppression, the number of retrieved M2 oocyte and fertilization, chemical and clinical pregnancy rates, and the miscarriage rate.

Official Title
-----------------
Progesterone-Primed Ovarian Stimulation Might be a Safe and Effective Alternative to GnRH-antagonist Protocol for Controlled-Ovarian Stimulation of Infertile PCOS Women

Conditions
-----------------
PCOS

Intervention / Treatment
-----------------
* Drug: Injection of Cetrorelix
* Drug: Oral insertion of dydrogeserone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Infertile PCOS women; aged 20-35 years; had BMI <35 kg/m2. Exclusion Criteria: Women who were younger than 20 or older than 35 years, obese of grade II or III, had poor OR, other causes of infertility, had previous attempts of IVF, had a history of repeated pregnancy loss.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group C<br> | Drug: Injection of Cetrorelix<br>* Patients received Cetrorelix subcutaneous injection on the day-6 in a dose of 0.25 daily till the trigger day.<br>|
| Active Comparator: Group S<br> | Drug: Oral insertion of dydrogeserone<br>* Patients received dydrogesterone in an oral dose of 20 mg/day in parallel with gonadotropin injection from day-2 of the menstrual cycle till the trigger day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Success rate of PPOS in relation to Premature LH surge suppression | the success rate of PPOS as regards the suppression of premature LH surge and prevention of the development of OHSS. | 12 months |